BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 16797984)

  • 21. Androsterone 3alpha-ether-3beta-substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship.
    Tchédam Ngatcha B; Luu-The V; Labrie F; Poirier D
    J Med Chem; 2005 Aug; 48(16):5257-68. PubMed ID: 16078844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The derivation of a potential transition state for the reduction reaction catalysed by 17beta-hydroxysteroid dehydrogenase--an approximate representation of its active site for use in drug design and discovery.
    Owen CP; Ahmed S
    Biochem Biophys Res Commun; 2004 May; 318(1):131-4. PubMed ID: 15110763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
    Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
    J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, chemical synthesis and biological evaluation of 3-spiromorpholinone/3-spirocarbamate androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
    Djigoué GB; Kenmogne LC; Roy J; Maltais R; Poirier D
    Bioorg Med Chem; 2015 Sep; 23(17):5433-51. PubMed ID: 26277760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3.
    Roy J; Fournier MA; Maltais R; Kenmogne LC; Poirier D
    J Steroid Biochem Mol Biol; 2014 May; 141():44-51. PubMed ID: 24434282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.
    Bey E; Marchais-Oberwinkler S; Negri M; Kruchten P; Oster A; Klein T; Spadaro A; Werth R; Frotscher M; Birk B; Hartmann RW
    J Med Chem; 2009 Nov; 52(21):6724-43. PubMed ID: 19831396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis of 3-spiromorpholinone androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
    Djigoué GB; Kenmogne LC; Roy J; Poirier D
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6360-2. PubMed ID: 24144853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of 17β-hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy.
    Ning X; Yang Y; Deng H; Zhang Q; Huang Y; Su Z; Fu Y; Xiang Q; Zhang S
    Steroids; 2017 May; 121():10-16. PubMed ID: 28267564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological evaluation of phenyl substituted 1H-1,2,4-triazoles as non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 2.
    Al-Soud YA; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    Arch Pharm (Weinheim); 2012 Aug; 345(8):610-21. PubMed ID: 22532378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities.
    Perspicace E; Cozzoli L; Gargano EM; Hanke N; Carotti A; Hartmann RW; Marchais-Oberwinkler S
    Eur J Med Chem; 2014 Aug; 83():317-37. PubMed ID: 24974351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
    Schuster D; Nashev LG; Kirchmair J; Laggner C; Wolber G; Langer T; Odermatt A
    J Med Chem; 2008 Jul; 51(14):4188-99. PubMed ID: 18533708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Fischer DS; Allan GM; Bubert C; Vicker N; Smith A; Tutill HJ; Purohit A; Wood L; Packham G; Mahon MF; Reed MJ; Potter BV
    J Med Chem; 2005 Sep; 48(18):5749-70. PubMed ID: 16134943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3Beta-alkyl-androsterones as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR+ and ER+ cell lines.
    Ngatcha BT; Laplante Y; Labrie F; Luu-The V; Poirier D
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):225-32. PubMed ID: 16359782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phytoestrogens as inhibitors of fungal 17beta-hydroxysteroid dehydrogenase.
    Kristan K; Krajnc K; Konc J; Gobec S; Stojan J; Rizner TL
    Steroids; 2005 Sep; 70(10):694-703. PubMed ID: 15936789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure.
    Karkola S; Alho-Richmond S; Wahala K
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):225-8. PubMed ID: 18822344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Curcumin derivatives inhibit testicular 17beta-hydroxysteroid dehydrogenase 3.
    Hu GX; Liang G; Chu Y; Li X; Lian QQ; Lin H; He Y; Huang Y; Hardy DO; Ge RS
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2549-51. PubMed ID: 20346654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of 3beta- and 17beta-hydroxysteroid dehydrogenase activities in rat Leydig cells by perfluorooctane acid.
    Zhao B; Chu Y; Hardy DO; Li XK; Ge RS
    J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):13-7. PubMed ID: 19818404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Lawrence HR; Vicker N; Allan GM; Smith A; Mahon MF; Tutill HJ; Purohit A; Reed MJ; Potter BV
    J Med Chem; 2005 Apr; 48(8):2759-62. PubMed ID: 15828812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors.
    Marchais-Oberwinkler S; Frotscher M; Ziegler E; Werth R; Kruchten P; Messinger J; Thole H; Hartmann RW
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):205-11. PubMed ID: 18950679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 6-Hydroxybenzothiophene ketones: potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) owing to favorable molecule geometry and conformational preorganization.
    Miralinaghi P; Schmitt C; Hartmann RW; Frotscher M; Engel M
    ChemMedChem; 2014 Oct; 9(10):2294-308. PubMed ID: 25044709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.